Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Therapy for Ocular Angiogenesis
Principles and Practice
Das, Friberg
Editore
Lippincott
Anno
2011
Pagine
464
ISBN
9781605476407
147,00 €
Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. In addition, retinal and choroidal neovascularization are the major causes of vision loss in this country. With the new era of anti-angiogenic therapies already in practice, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs.
Therapy for Ocular Angiogenesis: Principles and Practice covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the "Principles" of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the "Practice" of the therapy in many ocular diseases. Vision researchers in both academia and industry, as well as clinician scientists, have contributed chapters on different aspects of the angiogenic process, and clinical strategies to fight it. The book also includes chapters that deal with diabetic macular edema, and various therapeutic options for this condition.
A companion website includes the fully searchable text and an image bank.
--Discusses the principles of angiogenesis therapies and pathophysiology of ocular angiogenesis.
--Summarizes the clinical trials that led to approval of two FDA approved drugs in the field.
--Discusses ongoing clinical trials in the field.
--Describes potential new anti-angiogenesis drugs in the horizon.
--Discusses different drug delivery approaches in the eye.
I: PRINCIPLES
1: Tumor Angiogenesis: Concept Judah Folkman (Reproduction of the Hellen Keller Foundation Lecture 2006)
2: Retinal Neovascularization: Pathophysiology Robert Frank
3: Choroidal Neovascularization: Pathophysiology J. Ambati
4: VEGF the Major Player Patricia D'Amore
5: IFG-1 in Angiogenesis Lois Smith
6: Is It All the VEGF? Other Factors John Penn
7: Proteinases and Integrins Alexander Ljubimov and Arup Das
8: Endogenous Inhibitors David Hinton
9: Macular Edema: Molecular Mechanisms Arup Das
II: PRACTICE
1: Anti-VEGF Therapies in ARMD in Practice Jeff Heier
2: Novel Anti-VEGF Drugs in ARMD Currently in Trials Quan Nguyen
3: Safety of Anti-VEGF Drugs David Boyer and Thomas Friberg
4: Pharmacokinetics of Anti-VEGF Drugs Karl Casky
5: Anti-VEGF Therapies of Retinal Neovascularization Allen Ho
6: Anti-VEGF Therapies in Diabetic Macular Edema Lloyd Aiello
7: Steroids in ARMD and Macular Edema Jennifer Lim
8: Anti-VEGF Therapies in ROP Antonio Capone
9: Pharmacotherapy in Retinal Vein Occlusions Michael Ip
10: Intravitreal Injection: Technique and Complications Elias Reichel
11: Role of OCT in Management of ARMD and Macular Edema Srinivas Sadda
12: Role of Laser in the Era of Pharmacotherapy Thomas Friberg
13: PDT: Is It an Option? Albert Augustin
14: Combination Therapy: Future Richard Spaide
15: Gene Therapy in Ocular Angiogenesis Rajendra Kumar-Singh
16: Stem Cell Therapy Maria Grant
17: Drug Delivery in Posterior Segment: Challenges Prithvi Mruthyunjaya and Glenn Jaffe
18: Corneal Neovascularization Bala Ambati
19: Neovascular Glaucoma James Tsai
20: Financial Impact of Anti-Angiogenic Therapy George Williams
21: Future of Anti-Angiogenic Therapy Anthony Adamis
